About us
ANTUREC GmbH
ANTUREC is a privately owned pharmaceutical company devoted to anticancer drug development. The company was founded in 2020 by Wolfgang E. Berdel, Christian Schwöppe, and Ari Bizimis.
ANTUREC's CEOs are Wolfgang E. Berdel and Ari Bizimis, Christian Schwöppe is CSO of the company.
Clinical Member
Prof. Dr. med.
Wolfgang E. Berdel (CEO)
Hematologist/Oncologist/Clinical Pharmacologist
CEO and founder Anturec GmbH, Prof. emeritus, Dept. of Medicine A, UKM, Universitiy of Münster CEO, Founder Anturec GmbH, Inventor of Vascular Targeting with Tissue Factor and Nanocarrier Technology, Founder and CEO ELVESCA.
Business and Finances
Ari Bizimis (CEO)
Owner Mercurius private Equity,
Frankfurt. Founder and Co-CEO
ANTUREC, Founder and
Co-CEO ELVESCA
Research/Development/GMP Production
Dr. rer. nat.
Christian Schwöppe (CSO)
Biologist, Qualified Person (QP), Deputy Head of Production
Group Leader AG Vascular Targeting, Dept. Medicine A, UKM, Unversity of Münster.
CSO an founder Anturec GmbH.
QP ANTUREC and ELVESCA
Dr. rer. nat.
Caroline Brand
Biochemist, Head of Production,
Qualified Person (QP)
Senior Scientist AG Vascular Targeting,
Dept. Medicine A, UKM, University of
Münster
Dr. rer. nat.
Kathrin Heßling
Pharmacist, Head of Analytics,
Qualified Person (QP)
Senior Scientist AG Vascular Targeting,
Dept. Medicine A, UKM, University of
Münster
Heike Hintelmann
Medical-technical assistant,
Deputy Head of Analytics
Dept. Medicine A, UKM, University of Münster
University of Münster
The University of Münster – a renowned institution for excellent teaching, innovative research and a wide range of academic opportunities. The University of Münster, founded in 1780, stands for a long tradition of academic excellence and innovative spirit. With our over 250 degree programs and a wide range of research fields, we offer our students an inspiring learning environment in which they can develop their full potential.